Elise Siegert
YOU?
Author Swipe
View article: Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study
Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study Open
Objectives This study assessed how changes in lung function, skin fibrosis and digital ulceration (DU) burden predict mortality in patients with SSc-associated interstitial lung disease (SSc-ILD), the leading cause of death in SSc. Methods…
View article: OP0333 INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE
OP0333 INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE Open
View article: The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort
The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort Open
View article: Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort Open
Background Systemic sclerosis (SSc) primary heart involvement (SSc‐pHI) is one of the leading causes of mortality in SSc. We aimed to evaluate risk factors for SSc‐pHI and its progression and the outcomes in the EUSTAR (European Scleroderm…
View article: A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis Open
Objectives The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines for pulmonary arterial hypertension (PAH) recommend risk stratification to optimize management. However, the performance of generic PA…
View article: Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis
Identification of nuclear valosin-containing-protein-like as a target of anti-nuclear autoantibodies in systemic sclerosis Open
Objective To identify the target antigen of an anti-nuclear autoantibody (ANA) from a patient with a suspected systemic autoimmune disease and to study the autoantibody’s clinical association. Methods The index patient serum was screened f…
View article: Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database
Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database Open
Objective The objective of this study is to evaluate whether adding oral glucocorticoids to immunosuppressive therapy improves skin scores and ensures safety in patients with early diffuse cutaneous systemic sclerosis (dcSSc). Methods We p…
View article: Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis Open
View article: More than meets the eye
More than meets the eye Open
View article: Interdisziplinäre Zentren für Autoimmunerkrankungen in Deutschland
Interdisziplinäre Zentren für Autoimmunerkrankungen in Deutschland Open
View article: Predicting interstitial lung disease progression in patients with systemic sclerosis using attentive neural processes - a EUSTAR study
Predicting interstitial lung disease progression in patients with systemic sclerosis using attentive neural processes - a EUSTAR study Open
A bstract Background Systemic sclerosis (SSc) is an autoimmune disease with high mortality with lung involvement being the primary cause of death. Progressive interstitial lung disease (ILD) leads to a decline in lung function (forced vita…
View article: The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis—Interstitial Lung Disease in the European Scleroderma Trial and Research Database
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis—Interstitial Lung Disease in the European Scleroderma Trial and Research Database Open
Background and Objectives: In SSc, ILD is a major cause of morbidity and mortality. We aimed to investigate the performance of DLCO (diffusing capacity of lung carbon monoxide) and FVC (forced vital capacity) delta change (Δ) and baseline …
View article: Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival Open
ILD is the most prevalent pulmonary involvement in SSc, whereas the combination of ILD and PH is associated with the most detrimental survival.
View article: Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma Open
Importance Systemic sclerosis (SSc) sine scleroderma (ssSSc) is a subset of SSc defined by the absence of skin fibrosis. Little is known about the natural history and skin manifestations among patients with ssSSc. Objective To characterize…
View article: POS0121 COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT
POS0121 COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT Open
Background Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc). The 2022 ESC/ERS Guidelines recommend a comprehensive risk stratification at PAH diagnosis to guide optimized management. Several r…
View article: OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS
OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS Open
Background Pre-capillary pulmonary hypertension (precapPH) affects 9-15% of patients with systemic sclerosis (SSc) and may be associated with interstitial lung disease (ILD) of variable extent. Immunosuppressants (IMS) are standard of care…
View article: OP0244 DISEASE SEVERITY IS ASSOCIATED WITH OSTEOPOROSIS AND FRAGILITY FRACTURES IN PATIENTS WITH SYSTEMIC SCLEROSIS
OP0244 DISEASE SEVERITY IS ASSOCIATED WITH OSTEOPOROSIS AND FRAGILITY FRACTURES IN PATIENTS WITH SYSTEMIC SCLEROSIS Open
Background Patients with systemic sclerosis (SSc) are at an increased risk for osteoporosis (OP) and associated fragility fractures [1]. The prevalence of osteodensitometric OP has been estimated to range from 16% to 60% [2]. However, the …
View article: POS1243 THE ROLE OF TAPSE/SPAP RATIO IN PREDICTING PULMONARY HYPERTENSION AND MORTALITY IN THE SYSTEMIC SCLEROSIS EUSTAR COHORT
POS1243 THE ROLE OF TAPSE/SPAP RATIO IN PREDICTING PULMONARY HYPERTENSION AND MORTALITY IN THE SYSTEMIC SCLEROSIS EUSTAR COHORT Open
Background Early pulmonary arterial hypertension (PAH) diagnosis and treatment are crucial to improve systemic sclerosis (SSc) patients' outcomes. In PAH the progressive pulmonary vascular remodelling leads to an increasing load on the con…
View article: The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort
The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort Open
View article: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis Open
Objectives Gastroesophageal reflux disease (GERD) occurs frequently in patients with SSc. We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with lon…
View article: Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis
Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis Open
Background Systemic sclerosis (SSc) belongs to the group of connective tissue diseases and is associated with the occurrence of disease-specific autoantibodies. Although it is still controversial whether these antibodies contribute to path…
View article: Autologous hematopoietic stem cell transplantation improves long-term survival—data from a national registry
Autologous hematopoietic stem cell transplantation improves long-term survival—data from a national registry Open
View article: Sex influence on outcomes of patients with systemic sclerosis–associated interstitial lung disease: a EUSTAR database analysis
Sex influence on outcomes of patients with systemic sclerosis–associated interstitial lung disease: a EUSTAR database analysis Open
Objective Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. We aimed to investigate the impact of sex on SSc-ILD. Methods EUSTAR SSc patients with radiologically confirmed…
View article: Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort Open
Objectives Tocilizumab showed trends for improving skin fibrosis and prevented progression of lung fibrosis in systemic sclerosis (SSc) in randomised controlled clinical trials. We aimed to assess safety and effectiveness of tocilizumab in…
View article: Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort Open
View article: Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research Open
View article: Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region Open
Objectives The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) vary between geographical regions worldwide. The objectives of this study were to explore the differences in terms of prevalence, phenotype…
View article: Comprehensive Autoantibody Profiles in Systemic Sclerosis: Clinical Cluster Analysis
Comprehensive Autoantibody Profiles in Systemic Sclerosis: Clinical Cluster Analysis Open
Background Systemic sclerosis (SSc) belongs to the group of connective tissue diseases and is associated with the occurrence of disease-specific autoantibodies. Although it is still controversial whether these antibodies contribute to path…
View article: SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis
SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis Open
Systemic Sclerosis (SSc) is a clinically heterogeneous disease that includes an upregulation of type I interferons (IFNs). The aim of this observational study was to investigate the IFN-regulated protein Sialic Acid–Binding Ig-like Lectin …
View article: Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts
Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts Open